Founded in 2019

NovalGen

NovalGen is a privately held immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. Their dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated bispecific antibody products tailored to the needs of the patient, enabling life-enhancing treatments for people with haematologic and solid tumours. The company’s lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager using their breakthrough bispecific technology.